文献速递免疫规划卫生政策与健康促进

我们将会有新型百日咳疫苗吗?

Will we have new pertussis vaccines?
PubMed 文献 · Vaccine · 2017-11-24

尽管疫苗有效且接种覆盖率广,百日咳在各国仍未得到控制。现有全细胞和无细胞百日咳疫苗及减毒抗原含量加强疫苗,探索的重复接种、茧式接种和孕产妇免疫等策略除孕产妇免疫外均未证实有效,且孕产妇免疫亦不能最终控制百日咳。因此需要新型百日咳疫苗,多个候选疫苗处于早期临床前开发阶段,最先进的是减毒鼻用疫苗BPZE1,已在动物中显示强保护、安全且遗传稳定,并完成首次人体临床试验,显示安全、可短暂定植人类呼吸道并诱导免疫应答,目前正进行进一步临床开发。

要点

  • 现有百日咳疫苗及免疫策略未能控制百日咳,需要新型疫苗。
  • 候选新疫苗包括低内毒素全细胞疫苗、外膜囊泡、新佐剂或新增抗原的无细胞疫苗及减毒活疫苗。
  • 最先进的减毒鼻用疫苗BPZE1在动物中提供强保护且安全,首次人体试验显示安全、可短暂定植并诱导免疫应答。

核心结论

  • 尽管疫苗有效且接种覆盖率高,百日咳在各国仍未得到控制,需要新型百日咳疫苗。
  • 减毒鼻用疫苗BPZE1旨在减少百日咳鲍特菌的携带和传播,可能有助于最终控制百日咳。

研究设计与样本

  • 综述分析了现有百日咳疫苗及免疫策略的局限性,并总结了处于早期临床前开发阶段的新型候选疫苗。

主要发现

  • 现有疫苗包括用于基础免疫程序的白喉/破伤风/全细胞百日咳疫苗和白喉/破伤风/无细胞百日咳疫苗,以及推荐用于加强免疫的减毒抗原含量疫苗。
  • 探索的应对策略包括重复接种、茧式接种和孕产妇免疫,除孕产妇免疫外均未证实有效,且孕产妇免疫亦不能最终控制百日咳。
  • 候选新疫苗包括低内毒素全细胞疫苗、外膜囊泡、新制剂、含新佐剂或额外抗原的无细胞疫苗及减毒活疫苗。
  • 最先进的减毒鼻用疫苗BPZE1在小鼠和非人灵长类中提供强保护,在免疫缺陷动物中亦安全,体外和体内传代后遗传稳定,并具有有趣的免疫调节特性而无免疫抑制作用。
  • BPZE1已完成首次人体临床试验,显示安全、能短暂定植人类呼吸道并在定植受试者中诱导免疫应答。

局限性

  • 除孕产妇免疫外,重复接种和茧式接种等策略均未证实有效。
  • 孕产妇免疫亦不能最终控制百日咳。
  • 新型候选疫苗多处于早期临床前开发阶段,BPZE1仅完成首次人体临床试验,正在进一步临床开发中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite wide vaccination coverage with efficacious vaccines, pertussis is still not under control in any country. Two types of vaccines are available for the primary vaccination series, diphtheria/tetanus/whole-cell pertussis and diphtheria/tetanus/acellular pertussis vaccines, in addition to reduced antigen content vaccines recommended for booster vaccination. Using these vaccines, several strategies are being explored to counter the current pertussis problems, including repeated vaccination, cocoon vaccination and maternal immunization. With the exception of the latter, none have proven their effectiveness, and even maternal vaccination is not expected to ultimately control pertussis. Therefore, new pertussis vaccines are needed, and several candidates are in early pre-clinical development. They include whole-cell vaccines with low endotoxin content, outer membrane vesicles, new formulations, acellular vaccines with new adjuvants or additional antigens and live attenuated vaccines. The most advanced is the live attenuated nasal vaccine BPZE1. It provides strong protection in mice and non-human primates, is safe, even in immune compromised animals, and genetically stable after in vitro and in vivo passages. It also has interesting immunoregulatory properties without being immunosuppressive. It has successfully completed a first-in-man clinical trial, where it was found to be safe, able to transiently colonize the human respiratory tract and to induce immune responses in the colonized subjects. It is now undergoing further clinical development. As it is designed to reduce carriage and transmission of Bordetella pertussis, it may hopefully contribute to the ultimate control of pertussis.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Locht C. Will we have new pertussis vaccines? Vaccine. 2017. PMID: 29180031. doi:10.1016/j.vaccine.2017.11.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。